JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $445

JP Morgan analyst Jessica Fye has maintained an Overweight rating on BeOne Medicines (NASDAQ: ONC) and increased the price target from $425 to $445. This adjustment reflects a positive outlook on the company's performance.